

#44/2
7/9/99
C. Style


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

COATES et al.

Serial No.: 07/835,964

Filed: February 20, 1992



Examiner: J. Ford

Group Art Unit: 1611

For: 1,3-OXATHIOLANE NUCLEOSIDE ANALOGUES

REQUEST AND FIRST SUBMISSION FOR TRANSITIONAL PRACTICE
UNDER 37 C.F.R. §1.129(a)

Assistant Commissioner for Patents
Washington, DC 20231

SIR:

As a first submission pursuant to 37 C.F.R. §1.129, please amend the above-identified application as follows:

RECEIVED
TECH CENTER 1600/2900
99 JUN 30 PM 1:01

IN THE CLAIMS:

Please cancel claims 23, 30, 35, 36, and 40-42,

Please amend claims 25, 26, 28, 29, 31, and 37 as follows:

25. (Amended Twice) A method for treating a human [mammal] suffering from HIV infection comprising administering to said mammal a pharmaceutical composition comprising: the compound (-)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one, and a pharmaceutically acceptable carrier,
wherein said pharmaceutical composition further comprises another [antiviral] agent having antiviral activity, and
wherein the amount of the (+)-enantiomer corresponding to said compound is present in said composition is no more than 5% w/w, relative to the combined weight of (-) and (+)-enantiomers.

26. (Amended Twice) A method according to claim 25, wherein said [antiviral] agent is an acyclic nucleoside, an interferon, a renal excretion inhibitor, a nucleoside transport

06/29/1999 DIVISION 00000025 07835964

01 FC:146
02 FC:116
03 FC:103

760.00 OP
380.00 OP
144.00 OP

- 1 -

IAFG-14

35

I